Crescent Biopharma, Inc. Common Stock
$16.89
$0.12 (+0.72%)
$16.15Day Range$17.87
Key Statistics
Market Cap
$627.41M
Shares Outstanding
37.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 16, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$16.67
Day High
$17.87
Day Low
$16.15
Volume
3.12M
VWAP
$16.93
Prev Close
$16.77
Transactions
--
Acc. Volume
--
About Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
PHARMACEUTICAL PREPARATIONSSIC 283444 employees300 FIFTH AVENUE, WALTHAM, MA, 02451617-430-5595IPO Jun 16, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001253689
- Ticker Root
- CBIO
- SIC Code
- 2834
About Crescent Biopharma, Inc. Common Stock (CBIO) Stock
Crescent Biopharma, Inc. Common Stock (CBIO) closed the 2026-09-18 session at $16.89, up 0.72% versus the previous close (+0.12). The stock opened at $16.67 and traded between $16.15 and $17.87 during that session. Session trading volume was 3.1M shares. The volume-weighted average price (VWAP) is $16.93.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Crescent Biopharma, Inc. Common Stock has a market capitalization of $627.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CBIO is listed on the XNAS exchange. The company employs approximately 44 people. Crescent Biopharma, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2025-06-16.
On this page you can find market CBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.